Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. by Horsley, A, Davies, J, Gray, R, Macleod, K, Donovan, J, Aziz, Z, Bell, N, Rainer, M, Mt-Isa, S, Voase, N, Dewar, M, Saunders, C, Gibson, J, Parra-Leiton, J, Larsen, MD, Jeswiet, S, Soussi, S, Bakar, Y, Meister, MG, Tyler, P, Doherty, A, Hansell, D, Ashby, D, Hyde, S, Gill, D

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation by Horsley, A, Davies, J, Gray, R, MacLeod, K, Donovan, J, Aziz, Z, Bell, N, Rainer, M, Mt-Isa, S, Voase, N, Dewar, M, Saunders, C, Gibson, J, Parra-Leiton, J, Larsen, MD, Jeswiet, S, Soussi, S, Bakar, Y, Meister, MG, Tyler, P, Doherty, A, Hansell, D, Ashby, D, Hyde, S, Gill, DR

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial by Alton, EWFW, Armstrong, DK, Ashby, D, Bayfield, K, Bilton, D, Bloomfield, E, Boyd, A, Brand, J, Buchan, R, Calcedo, R, Carvelli, P, Chan, M, Cheng, S, Collie, D, Cunningham, S, Davidson, H, Davies, G, Davies, J, Davies, L, Dewar, M, Doherty, A, Donovan, J, Dwyer, N, Elgmati, H, Featherstone, R, Gavino, J, Gea-Sorli, S, Geddes, D, Gibson, J, Gill, D, Greening, A, Griesenbach, U, Hansell, D, Harman, K, Higgins, T, Hodges, S, Hyde, S, Hyndman, L, Innes, J, Jacob, J, Jones, S, Keogh, B, Limberis, M, Lloyd-Evans, P, Maclean, A, Manvell, M, McCormick, D, McGovern, M, McLachlan, G, Meng, C, Montero, M, Milligan, H, Moyce, L, Murray, G, Nicholson, A, Osadolor, T, Parra-Leiton, J, Porteous, D, Pringle, I, Punch, E, Pytel, K, Quittner, A, Rivellini, G, Saunders, C, Scheule, R, Sheard, S, Simmonds, N, Smith, K, Smith, S, Soussi, N, Soussi, S, Spearing, E, Stevenson, B, Sumner-Jones, S, Turkkila, M, Ureta, R, Waller, M, Wasowicz, M, Wilson, J, Wolstenholme-Hogg, P

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with... by Alton, EWFW, Armstrong, DK, Ashby, D, Bayfield, KJ, Bilton, D, Bloomfield, EV, Boyd, AC, Brand, J, Buchan, R, Calcedo, R, Carvelli, P, Chan, M, Cheng, SH, Collie, DS, Cunningham, S, Davidson, HE, Davies, G, Davies, JC, Davies, LA, Dewar, MH, Doherty, A, Donovan, J, Dwyer, NS, Elgmati, HI, Featherstone, RF, Gavino, J, Gea-Sorli, S, Geddes, DM, Gibson, JSR, Gill, DR, Greening, AP, Griesenbach, U, Hansell, DM, Harman, K, Higgins, TE, Hodges, SL, Hyde, SC, Hyndman, L, Innes, JA, Jacob, J, Jones, N, Keogh, BF, Limberis, MP, Lloyd-Evans, P, Maclean, AW, Manvell, MC, McCormick, D, McGovern, M, McLachlan, G, Meng, C, Montero, MA, Milligan, H, Moyce, LJ, Murray, GD, Nicholson, AG, Osadolor, T, Parra-Leiton, J, Porteous, DJ, Pringle, IA, Punch, EK, Pytel, KM, Quittner, AL, Rivellini, G, Saunders, CJ, Scheule, RK, Sheard, S, Simmonds, NJ, Smith, K, Smith, SN, Soussi, N, Soussi, S, Spearing, EJ, Stevenson, BJ, Sumner-Jones, SG, Turkkila, M, Ureta, RP, Waller, MD, Wasowicz, MY, Wilson, JM, Wolstenholme-Hogg, P, UK Cystic Fibrosis Gene Therapy Consortium